BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

The FDA approved 50 novel drugs that contained an active ingredient ... Both treatments are monoclonal antibodies that target beta plaques in the brain, though Kisunla is infused every four ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Rakesh Jain PhD, Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk ...

The target of Datroway is TROP2 ... is also seeking to expand use of the drug to other cancers. Last week, the FDA accepted an application seeking approval of the ADC for EGFR-mutated non-small ...

The FDA also approved Netherlands-based Qiagen's ... Lumakras is an oral drug designed to target a mutated form of the KRAS gene, which occurs in 3% to 5% of colorectal cancers, while Vectibix ...